Gunderson Dettmer Wins China Business Law Journal’s 2024 “Deals of the Year”

We are thrilled to announce that Gunderson Dettmer has been recognized in China Business Law Journal’s 2024 “Deals of the Year” report for our participation in a standout transaction in the PE/VC category:

Candid Therapeutics’ $370 Million Series A Financing

Gunderson Dettmer represented Qiming Venture Partners and Foresite as investors in the $370 million Series A financing of Candid Therapeutics, a biotechnology company dedicated to developing innovative therapies for autoimmune diseases.

• China Deal Team (Qiming Venture Partners)
  • • Led by Zhen Liu and included Shuyue Tan and Chen Gao

• U.S. Deal Team (Foresite)
  • • Led by Jeffrey Thacker and included Matthew Rietfors and Yushen Liu

This recognition underscores our global expertise and commitment to delivering exceptional results for our clients in the China venture ecosystem. Congratulations to our clients and teams for their outstanding work!